Genzyme Corporation: PharmaVitae Profile 2016 now available at ReportsandReports
Dallas, TX: ReportsandReports announce Genzyme Corporation: PharmaVitae Profile 2016 Market Research Report in its Store.
Browse complete Report at http://www.reportsandreports.com/market-reports/genzyme-corporation-pharmavitae-profile/
This analysis examines the historical and forecast performance for Genzyme in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
- Benchmark Genzyme's performance against key rivals in the prescription pharmaceutical sector
- See how the company's core products of Cerezyme, Fabrazyme and Myozyme/Lumizyme will continue to act as the primary sales growth drivers
- Assess the impact of the recent contamination of the Allston manufacturing facility on the company's performance through 2009
Table Of Contents
ABOUT DATAMONITOR HEALTHCARE 2
About the PharmaVitae team 2
Chapter 1 About this profile 3
PharmaVitae Explorer database 3
Chapter structure 3
Executive summary 3
Quarterly news update 3
Company introduction 3
Company sales 4
Company financials 4
Key products and competitors 4
Data sourcing 4
Sales data 4
Analyst consensus 4
Chapter 2 Executive summary 5
Key findings 5
Prescription pharmaceutical sales and growth rate performance, 2002-14 6
Financial performance, 2002-14 8
Genzyme: PharmaVitae forecasts at a glance 9
Strategic insight 10
Genzyme success in ultra-niche markets 10
Combination of fast revenue growth and margin improvement leads to explosive profit growth 10
With the blockbuster model under threat, Genzyme's niche market strategy looks set to hold firm 11
High-risk blockbuster model out-dated? 11
Genzyme's niche market-targeting an alternative strategy 11
Greater economies of scale as rare genetic disorders franchise expands 12
Allston facility contamination impact Genzyme's 2009 performance 12
Genzyme's spread-risk strategy 13
The renal franchise is Genzyme's first major example of therapeutic diversification 13
Further therapeutic diversification, emerging player in oncology 14
Acquisition of Bayer products adds further strength to oncology offering 14
SWOT analysis 18
Strengths 18
Weaknesses 19
Opportunities 19
Threats 20
Table of Contents 21
Table of figures 23
Chapter 3 Quarterly news update 24
Product developments 24
Deals and alliances 25
Product deals 25
Technology deals 26
M&A activity 27
Company announcements 28
Future product milestones 29
Chapter 4 Company introduction 30
Key findings 30
Background 31
Key corporate developments 32
M&A history 33
Bone Care International 33
AnorMED acquisition 34
Mozobil: the catalyst 34
Bioenvision 35
Current corporate structure 35
Biotherapeutics 35
LSDs 36
The rarity of LSDs offers a significant niche opportunity 36
Genetics/diagnostics 37
Chapter 5 Company sales 38
Key findings 38
Prescription pharmaceutical sales and growth rate analysis, 2002-14 39
Product analysis 42
Product analysis, 2002-08 44
Product analysis, 2008-14 47
Therapy area analysis 51
Geographic analysis 55
Launch/core/expiry analysis 58
Explanation of launch/core/expiry analysis 58
Launch analysis, 2008-14 59
Core analysis, 2008-14 60
Expiry analysis, 2008-14 61
Launch/core/expiry configuration, 2008-14 62
Molecule type analysis 64
Externalization analysis 68
Chapter 6 Company financials 71
Key findings 71
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08 72
Operating costs and profit analysis 74
Operating costs and profit analysis, 2002-08 75
Operating cost ratio and profit margin analysis, 2002-08 76
Operating cost ratio and profit margin analysis, 2008-14 77
Operating costs and profit analysis, 2008-14 78
Chapter 7 Key products and competitors 80
Key findings 80
Overview 81
Endocrine, metabolic and genetic disorders 82
Cerezyme 82
Overview 83
Sales forecast 84
A rare disorder, but significant sales growth 84
Allston manufacturing facility contamination impacts 2009 sales 84
Threat from Shire and Protalix toward the end of the forecast period 85
Long term threat from pharmacological chaperones, Shire/Amicus's Plicera 86
Myozyme/Lumizyme 87
Overview 87
Sales forecast 88
Genzyme's key growth driver 88
Development of Lumizyme expected to provide boost to sales 89
Fabrazyme 90
Overview 90
Sales forecast 91
Comprehensive exclusivity 91
Shire suffers blow with Replagal 91
Amicus could provide competition in the long term 92
Genitourinary 93
Renagel/Renvela 93
Overview 94
Sales forecast 95
Therapeutic diversification through M&A 95
Established product 95
Strong sales force and good safety... 95
...backed by the NKF 95
Competition does exist 96
Renvela developed in order to consolidate Genzyme's position as number one 96
Label expansion into CKD patients not on dialysis 96
Hectorol 97
Overview 97
Sales forecast 98
Product gained through acquisition 98
Used as a complimentary product 98
Competition from Amgen 98
Oncology 99
Mozobil 99
Overview 99
Sales forecast 100
Innovative therapy supporting Genzyme's exploration into oncology 100
Strong clinical trial data 100
Clolar 102
Overview 102
Sales forecast 103
Acquisition of Bioenvision provided Clolar and boosted Genzyme's oncology offering 103
While approval in AML will significantly broaden Clolar's label, increased economic constraints on healthcare systems may restrict its uptake 103
Price and further competition will impede growth 103
Central nervous system 105
Campath 105
Overview 105
Sales forecast 106
Phase II data show superior efficacy compared to Rebif 106
Safety concerns 107
Future market potential 107
Chapter 8 Appendix 109
R&D pipeline 109
References 110
Datamonitor reports 110
Abbreviations 110
About Datamonitor 112
About Datamonitor Healthcare 112
Datamonitor consulting 112
Disclaimer 114
List of Tables
Table 1: Genzyme - PharmaVitae forecasts at a glance 9
Table 2: Genzyme key product developments, 2009 24
Table 3: Genzyme product deals and alliances, 2009 25
Table 4: Genzyme technology deals and alliances, 2009 26
Table 5: Genzyme M&A activity, 2009 27
Table 6: Genzyme company announcements, 2009 28
Table 7: Genzyme future product milestones, 2009-11 29
Table 8: Genzyme's acquisition history (2000-2008) 33
Table 9: Genzyme product portfolio overview ($m), 2002-08 44
Table 10: Genzyme product portfolio overview ($m), 2008-14 47
Table 11: Genzyme prescription pharmaceutical sales by therapy area ($m), 2008-14 53
Table 12: Genzyme prescription pharmaceutical sales by geographic region ($m), 2008-14 56
Table 13: Genzyme launch portfolio overview ($m), 2008-14 59
Table 14: Genzyme core portfolio overview ($m), 2008-14 60
Table 15: Genzyme expiry portfolio overview ($m), 2008-14 61
Table 16: Genzyme prescription pharmaceutical sales by molecule type ($m), 2008-14 66
Table 17: Genzyme prescription pharmaceutical sales by source ($m), 2008-14 69
Table 18: Total Genzyme sales by business unit ($m), 2002-08 72
Table 19: Genzyme operating revenue/cost analysis ($m), 2002-08 75
Table 20: Genzyme operating cost ratio analysis (% of total revenues), 2002-08 76
Table 21: Genzyme operating cost ratio analysis (% of total revenues), 2008-14 77
Table 22: Genzyme operating revenue/cost analysis ($m), 2008-14 78
Table 23: Key products overview 81
Table 24: Cerezyme: overview 83
Table 25: Cerezyme: sales forecast ($m), 2008-14 84
Table 26: Myozyme/Lumizyme: overview 87
Table 27: Myozyme/Lumizyme: sales forecast ($m), 2008-14 88
Table 28: Fabrazyme: overview 90
Table 29: Fabrazyme: sales forecast ($m), 2008-14 91
Table 30: Renagel/Renvela: overview 94
Table 31: Renagel/Renvela: sales forecast ($m), 2008-14 95
Table 32: Hectorol: overview 97
Table 33: Hectorol: sales forecast ($m), 2008-14 98
Table 34: Mozobil: overview 99
Table 35: Mozobil: sales forecast ($m), 2008-14 100
Table 36: Clolar: overview 102
Table 37: Clolar: sales forecast ($m), 2008-14 103
Table 38: Campath: overview 105
Table 39: Campath (CNS): sales forecast ($m), 2008-14 106
Table 40: Genzyme's R&D pipeline (Phase I-registration) 109
List of Figures
Figure 1: The PharmaVitae Explorer 3
Figure 2: Genzyme prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 7
Figure 3: Genzyme's financial performance ($m), 2002-14 8
Figure 4: Genzyme's therapy area diversification, 2002-14 16
Figure 5: Genzyme SWOT analysis 18
Figure 6: Genzyme timeline 32
Figure 7: Current corporate structure 35
Figure 8: Genzyme prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 40
Figure 9: Key product sales ($m), 2002-14 43
Figure 10: Genzyme key sales growth drivers and resistors ($m), 2002-08 45
Figure 11: Genzyme key sales growth drivers and resistors ($m), 2008-14 48
Figure 12: Genzyme prescription pharmaceutical sales by therapy area ($m), 2002-14 52
Figure 13: Genzyme prescription pharmaceutical sales by geographic region ($m), 2002-14 55
Figure 14: Genzyme launch/core/expiry configuration ($m), 2008-14 62
Figure 15: Genzyme prescription pharmaceutical sales by molecule type ($m), 2002-14 65
Figure 16: Genzyme prescription pharmaceutical sales by source ($m), 2002-14 68
Figure 17: Genzyme operating revenue/cost analysis ($m), 2002-14 74
Browse all Healthcare Market Research Reports
Browse all Datamonitor Market Research Reports
Browse all Newly Published Market Research Reports
Related Reports:
Genzyme Corporation Market Share Analysis
Genzyme Corporation - SWOT Analysis
Mitsubishi Tanabe Pharma Corporation: PharmaVitae Profile
About Us:
Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.
Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.reportsandreports.com/
Customer comments
No comments were found for Genzyme Corporation: PharmaVitae Profile 2016 now available at ReportsandReports. Be the first to comment!